GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Beta

InMed Pharmaceuticals (FRA:MWG0) Beta : -0.43 (As of Jun. 16, 2024)


View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-16), InMed Pharmaceuticals's Beta is -0.43.


InMed Pharmaceuticals Beta Historical Data

The historical data trend for InMed Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Beta Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.13 1.91 1.62 0.80 -

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 - 0.18 -0.33 -0.36

Competitive Comparison of InMed Pharmaceuticals's Beta

For the Biotechnology subindustry, InMed Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Beta falls into.



InMed Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


InMed Pharmaceuticals  (FRA:MWG0) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


InMed Pharmaceuticals Beta Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (FRA:MWG0) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (FRA:MWG0) Headlines

No Headlines